Femasys Inc. reported a loss and a big drop in sales for the third quarter of 2026.

Nov 14, 2026, 9:06 AM ETResultsRead the original at globenewswire.com

Neutral

Femasys' total loss grew to $4.56 million, though its loss per share narrowed to $0.53 from $2.05. Sales fell 44.5%, but new funding and trial progress balance those setbacks, so the update points neither clearly up nor down.

FEMY · Femasys Inc.

AI read · Neutral

The AI's read

The new money is intended to pay for the U.S. sales build-out and FemBloc trial. More trial sites and new care partnerships show those programs are moving ahead. But sales fell and the total loss grew, even as the loss per share narrowed. These facts point in different directions.

Get alerts for FEMY

Follow Femasys Inc. (FEMY) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for FEMY

Free on the App Store and Google Play, or on the web.